Worldwide guidelines for respiratory tract infections: Community-acquired pneumonia

International Journal of Antimicrobial Agents

Volumn 18, Issue SUPPL.1, 2001, Pages 39-44

  Dalhoff, K ^a  

^a UNIVERSITY OF LÜBECK   (Germany)

Author keywords

Canada; Community acquired pneumonia; Europe; Guidelines; Respiratory tract infections; Treatment; USA

Indexed keywords

ANTIINFECTIVE AGENT; MACROLIDE;

ANTIBIOTIC RESISTANCE; BACTERIAL PNEUMONIA; COMMUNICABLE DISEASE; HEALTH; HUMAN; MICROBIOLOGY; PRACTICE GUIDELINE; RESPIRATORY TRACT INFECTION; REVIEW; STANDARD;

ANTI-BACTERIAL AGENTS; COMMUNITY-ACQUIRED INFECTIONS; DRUG RESISTANCE, BACTERIAL; HUMANS; MACROLIDES; PNEUMONIA, BACTERIAL; PRACTICE GUIDELINES; RESPIRATORY TRACT INFECTIONS; WORLD HEALTH;

EID: 0038133174     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0924-8579(01)00405-8     Document Type: Article

References (40)

1. Huchon G, Chidiac C, Delaval P, et al. Management of community-acquired lower respiratory tract infection in the adult. Recommendations by the French Language Society of Pneumology with collaboration of the French Language Society of Infectious Pathology, from the recommendations of the European Respiratory Society. Rev Mal Respir 1999;16:224-33.
2. Dorca J, Bello S, Blanquer J, et al. The diagnosis and treatment of community-acquired pneumonia. Arch Bronconeumol 1997;33:240-6.
3. Canadian Community-Acquired Pneumonia Consensus Conference Group, Mandell LA, Niederman MS. Antimicrobial treatment of community-acquired pneumonia in adults: a conference report. Can J Infect Dis 1993;4:25-8.
4. Niederman MS, Bass JB Jr, Campbell GD, et al. Guidelines for the initial management of adults with community-acquired pneumonia: diagnosis, assessment of severity, and initial antimicrobial therapy. Am Rev Respir Dis 1993;148:1418-26.
5. The British Thoracic Society. Guidelines for the management of community-acquired pneumonia in adults admitted to hospital. Br J Hosp Med 1993;49:346-50.
6. Gialdroni Grassi G, Bianchi L. Guidelines for the management of community-acquired pneumonia in adults. Monaldi Arch Chest Dis 1995;50:21-7.
7. Schaber T, Dalhoff K, Ewig S, Lorenz J, Wilkens H. Deutsche Gesellschaft für Pneumologie: Empfehlungen zur Therapie der ambulant erworbenen Pneumonie. Pneumologie 1998;52:450-62.
8. European Respiratory Society. ERS Task Force Report. Guidelines for management of adult community-acquired lower respiratory tract infections. Eur Respir J 1998;11:986-91.
9. Infectious Diseases Society of America, Bartlett JG, Breiman RF, Mandell LA, File TM Jr. Community-acquired pneumonia in adults: guidelines for management. Clin Infect Dis 1998;26:811-38.
10. Lawrence L, Hall MJ. Nineteen hundred ninety-seven summary: National Hospital Discharge Survey. Adv Data 1999;308:1-16.
11. Owings MF, Lawrence L. Detailed diagnoses and procedures: National Hospital Discharge Survey, 1997. Vital Health Stat 1999;13:1-157.
12. Graves EJ, Owings MF. Nineteen hundred ninety-five summary: National Hospital Discharge Survey. Adv Data 1997;291:1-10.
13. Kmietowicz Z. WHO warns of threat of 'superbugs'. Br Med J 2000;320:1624.
14. Woodhead M. Empirical antibiotic therapy and lower respiratory tract infections: European guidelines and current practices. Monaldi Arch Chest Dis 1995;50:472-6.
15. Marrie TJ. Risks and outcomes in community-acquired pneumonia. Can Respir J 1999;6(Suppl. A):6A-9A.
16. Neill AM. Community-acquired pneumonia: aetiology and usefulness of severity criteria on admission. Thorax 1996;51:1010-6.
17. Flanagan PG. Diagnosis of ventilator-associated pneumonia. J Hosp Infect 1999;41:87-99.
18. Rubins JB, Janoff EN. Community-acquired pneumonia. Tailoring management of adult patients according to risk category. Postgrad Med 1997;102:45-7, 52, 55-62.
19. Fine M, Smith MA, Carson CA, et al. Prognosis and outcomes of patients with community-acquired pneumonia. A meta-analysis. J Am Med Assoc 1996;275:134-41.
20. Doern GV, Pfaller MA, Kugler K, Freeman J, Jones RN. Prevalence of antimicrobial resistance among respiratory isolates of Streptococcus pneumoniae in North America: results from the SENTRY antimicrobial surveillance program. Clin Infect Dis 1997;27:764-70.
21. Doern GV, Brueggemann AB, Huynh H, Wingert E. Antimicrobial resistance with Streptococcus pneumoniae in the United States, 1997-1998. Emerg Infect Dis 1999;5:757-65.
22. Felmingham D, Gruneberg RN. The Alexander Project 1996-1997: latest susceptibility data from this international study of bacterial pathogens from community-acquired lower respiratory tract infections. J Antimicrob Chemother 2000;45:191-203.
23. Shortridge VD, Doern GV, Brueggemann AB, Beyer JM, Flamm RK. Prevalence of macrolide resistance mechanisms in Streptococcus pneumoniae isolates from a multicenter antibiotic resistance surveillance study conducted in the United States in 1994-1995. Clin Infect Dis 1999;29:1186-8.
24. Pontani D, Washton H, Boucillon S, Johnson J. Susceptibility of European respiratory tract isolates to trovafloxacin, ciprofloxacin, clarithromycin, azithromycin and ampicillin. Eur J Clin Microbiol Infect Dis 1998;17:413-9.
25. Doern GV, Pfaller MA, Erwin ME, Brueggemann AB, Jones RN. The prevalence of fluoroquinolone resistance among clinically significant respiratory tract isolates of Streptococcus pneumoniae in the United States and Canada - 1997 results from the SENTRY Antimicrobial Surveillance Program. Diagn Microbiol Infect Dis 1998;32:313-6.
26. Blondeau JM, Laskowski R, Bjarnason J, Stewart C. Comparative in vitro activity of gatifloxacin, grepafloxacin, moxifloxacin and trovafloxacin against 4151 Gram-negative and Gram-positive organisms. Int J Antimicrob Agents 2000;14:45-50.
27. Hogan PA, Sheehan DJ. Macrolide susceptibility and β-lactamases production among Haemophilus influenzae isolates in the United States, 1996-1997. Antimicrob Agents Chemother 1998;42:3313-4.
28. Heffelfinger JD, Dowell SF, Jorgensen JH, et al. Management of community-acquired pneumonia in the era of pneumococcal resistance: a report from the Drug-Resistant Streptococcus pneumoniae Therapeutic Working Group. Arch Intern Med 2000;160:1399-408.
29. Gleason PP, Meehan TP, Fine JM, Galusha DH, Fine MJ. Medical outcomes and antimicrobial costs with the use of the American Thoracic Society guidelines for outpatients with community-acquired pneumonia. J Am Med Assoc 1997;278:32-9.
30. Craig WA. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis 1998;26:1-10.
31. Suez D, Szefler SJ. Excessive accumulation of mucus in children with asthma: a potential role for erythromycin? A case discussion. J Allergy Clin Immunol 1986;77:330-4.
32. Rubin BK, Druce H, Ramirez OE, Palmer R. Effect of clarithromycin on nasal mucus properties in healthy subjects and in patients with purulent rhinitis. Am J Respir Crit Care Med 1997;155:2018-23.
33. Tamaoki J, Takeyama K, Tagaya E, Konno K. Effect of clarithromycin on sputum production and its Theological properties in chronic respiratory tract infections. Antimicrob Agents Chemother 1995;39:1688-90.
34. Amsden GW. Advanced-generation macrolides: tissue-directed antibiotics. Int J Antimicrob Agents 2001;18(Suppl. 1).
35. Tulkens PM. Marcolides: pharmacokinetics and pharnacodynamics. Int J Antimicrob Agents 2001;18(Suppl. 1).
36. Wise R. The pharmacokinetics of azithromycin. Rev Contemp Pharmacother 1994;5:329-40.
37. Rodvold KA, Gotfried MH, Danziger LH, Servi RJ. Intrapulmonary steady-state concentrations of clarithromycin and azithromycin in healthy adult volunteers. Antimicrob Agents Chemother 1997;41:1399-402.
38. Conte JE Jr, Golden J, Duncan S, McKenna E, Lin E, Zurlinden E. Single-dose intrapulmonary pharmacokinetics of azithromycin, clarithromycin, ciprofloxacin, and cefuroxime in volunteer subjects. Antimicrob Agents Chemother 1996;40:1617-22.
39. Conte JE Jr, Golden JA, Duncan S, McKenna E, Zurlinden E. Intrapulmonary pharmacokinetics of clarithromycin and of erythromycin. Antimicrob Agents Chemother 1995;39:334-8.
40. Marrie T, Lau CY, Wheeler SL, et al. A controlled trial of a critical pathway for treatment of community-acquired pneumonia. J Am Med Assoc 2000;283:749-55.